BACKGROUND: While immunotherapy combined with standard of care (SOC) is often used for high-grade glioma (HGG), there have been few comparisons between immunotherapy combined SOC treatment (IMCT) and SOC alone. For clinicians seeking to increase immunotherapies' efficacy, it is important to understand what interventions exist and their relative effectiveness. METHODS: The Cochrane Library, Embase, Medline, and the
Web of Science Core Collection were systematically searched by two librarians. Retrieved hits were screened for inclusion. Subgroup analysis and Cox proportional hazards modeling was used to examine factors associated with overall survival (OS). Progressionfree survival (PFS), objective response rate (ORR), and occurrence rate of adverse events (AE) were included as secondary endpoints to further assess the efficacy and safety of IMCT. GRADE profiler was applied to assess the quality of evidence. This study is registered with PROSPERO, number CRD42019112356 RESULTS: The search yielded 2315 results of which 13 met eligibility criteria. We identified 13 publications, 14 randomized controlled trials (RCTs), and 5 historical-matched controlled trials(HMCTs). In a fixed effects model, Compared to SOC alone, IMCT improved OS (HR = 0.82; 95% CI 0.74-0.90; p < 0.0001), PFS (HR = 0.61; 95% CI 0.40-0.92; p = 0.019), ORR (RR = 2.13; 95% CI 2.56-2.92; p < 0.0001) bur increased the occurrence rate of AE (p < 0.0001). CONCLUSIONS: It suggests that IMCT compared to SOC alone have considerable effectiveness. Our findings support the use of immunotherapy in brain tumor to improve HGG outcomes.
Background
High-grade gliomas (HGG), mainly anaplastic astrocytoma (AA; WHO grade III) and glioblastoma multiforme (GBM; WHO grade IV), are the most common primary tumors in the central nervous system (CNS) in adults [1, 2] . HGG has long been a concern in the society.
Despite remarkable advances in neurosurgery, radiotherapy and chemotherapy, there was no dramatic progress in survival improvement of patients with HGG over the past half century and these patients still face a poor prognosis. Standard of care for HGG usually entails surgery followed by maximal surgical resection, followed by concurrent high-dose radiation and temozolomide (TMZ) chemotherapy, sometimes including carmustine and lomustine as alternative chemotherapy. Resistance to chemotherapy of HGG appears to another concerning issue. The possible susceptibility of GBM to gene therapy and immunotherapy has been explored.
The concept of cancer immunotherapy can be tracked back to William Coley who first use bacteria to cure cancer in 1893. It means that the immune system can recognize and control tumor growth. In recent years, immunotherapies are gaining much research attention and exceedingly more evidences show that high grade gliomas can get certain benefits from it. The median overall survival (OS) times of SOC were 37.6 and 14.4 months for AA(WHO grade III) and GBM(WHO grade IV) [3] . However, six meta-analysis respectively published in 2014 and 2018 indicated improved OS and PFS were obtained through immunotherapy in HGG patients [4] [5] [6] [7] [8] [9] . The interventions of current systematic review included immunotherapy categorized as follows: In order to verify and quantify the efficacy and safety of the combination of immunotherapy and SOC, current meta-analysis was started by utilizing survival data of 13 published papers. We also hope to inform clinicians which kind of IMCT is more effective when combined with SOC for patients with HGG.
Methods

Search strategy and selection criteria
For this systematic meta-analysis, we searched for randomized controlled trials (RCTs) published from the date of database inception to December 1,2018, comparing immunotherapy combined SOC treatment (IMCT) and standard of care (SOC) in adults (age ≥18), with a diagnosis of HGG according to standardized diagnostic criteria.
Two authors (S.N. Zhang and X.D. Hu) searched online using thematic and free words as a strategy through the Cochrane Library/Embase/Pubmed/Web of science four libraries for relevant articles published up to December 1, 2018. Search terms included "glioma", " astrocytoma", "glioblastoma", "immunity", "immunotherapy", "viruses", "humans" and "randomized". An English language restriction was pronounced. Clinical trials registered on the website (http://ClinicalTrials. gov) were also explored.
The following inclusion criteria have been adopted: therapy intervention restricted in IMCT, adults with HGG, two arms with IMCT and SOC. SOC entails surgery, radiotherapy, and chemotherapy. All included studies are English.
The following exclusion criteria have been adopted: lack of relevant outcome data, trials with non-standard of care control arm, phase Ⅰ trials, phase Ⅱ single arm trials, animal or cell trials. Abstracts and presentations from all major conference proceedings were excluded.
Data extraction and quality assessment
Two investigators (N.Y. Wen and X.M. Liu) extracted relevant information from the included articles. The HR described as a more suitable measure for analyzing time-toevent outcomes than odds ratio (OR) or relative risk (RR) was extracted [10, 11] . When a direct report of HR and 95 % CI was not available, estimated value was derived indirectly from Kaplan-Meier curves according to the methodology described by Jayne F Tierney [10] .
Censored dots in graphic data were extracted by software Engauge Digitizer 4.1 (http://digitizer.sourceforge.net/).
For the RCTs and non-randomized controlled trials, anothor two investigators (X.Y. Peng and L. Fan) independently assessed the risk of bias with the Cochrane risk of bias tool [11] and and Newcastle-Ottawa scale (NOS) [12] respectively. Discrepancies were arbitrated by S.N. Zhang. GRADE profiler (version 3.6, the GRADE WorkingGroup, http://www.gradeworkinggroup.org) was used to assess the quality of evidence for each endpoint. Factors that would downgrade the quality (risk of bias, inconsis-tency, indirectness, imprecision, and publication bias) or upgrade the quality (large effect, plausible confounding, and dose response) were assessed. Quality of evidence was assessed as "low," "moderate," and "high."
The mean study sample size was 128, participants ranging from 13 to 745. Potential sources of bias in trial design and investigational methods graded according to the Cochrane's Collaborate risk of bias tool suggested most of the RCTs was open-label trials, and thereof 6 trials adopted double-blinding. NOS scale (Newcastle Ottawa quality assessment) for cohort study was used to assess the risk of bias of non-randomized historical matched control trials [13] . The quality of publications was assessed as 2a level. [11] Statistical analysis Details of our statistical analyses were performed by STATA (version 15.0 for Windows; https://www.stata.com/). The risk of bias with the Cochrane risk of bias tool was performed by Reviewer Manager (version 5.2.1 for Windows; http://ims.cochrane.org/revman/). The primary end point was overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and occurrence rate of adverse events (AE); secondary end points were subgroup analysis, meta regression, heterogeneity exploration and cumulative metaanalysis.
Hazard ratio and 95% confidence intervals (CIs) were calculated for OS and PFS. Risk ratios and 95% CIs were calculated for ORR and AE. A random-effects model was used for data synthesis in the presence of significant heterogeneity, while a fixed-effects model was used when there was no significant heterogeneity. Heterogeneity across trials was assessed with I 2 test, and I 2 > 50%, p < 0.1 suggested there was significant heterogeneity.
Subgroup analysis was conducted. Heterogeneity across entire study were examined by galbraith radial plot. The cumulative meta-analysis for OS were conducted according to the year in which they first published.
Sensitivity analysis was performed to explore the impact of an individual study by deleting 1 study each time. Publication bias was examined by Begg's funnel plots.
Results
Overall, 2,315 citations were identified by the researchers and 68 potentially eligible articles were retrieved in full text. We excluded 55 reports, but included 2 additional studies from other sources, resulting in 13 publications describing 14 RCTs published and Table 1 ). The quality of the evidence was assessed with GRADE profiler. Most of the endpoints had high quality due to certain efficacy. Non-randomized HMCTs were assessed as moderate quality. The GRADE profiler summary is described in the Supplementary Table   2 .
We summarized basic characteristics of studies including design, NCT number, clinical phase, immunotherapy type and clinical characteristic of patients in each trial and so on in the Supplementary Table 2 . The included participants had a mean age of 51.15 years, male is 62.55%. The included participants had a mean median OS of 72.06 weeks in IMCT while mean median OS of SOC is 46.84 weeks (p = 0.0131). Median OS of GBM was shorter than AA patients (p < 0.0001). Patients benefited from IMCT in both GBM and AA patients (p < 0.0001) ( Supplementary Figure 1 ).
Primary endpoints
According to GRADE, the quality of evidence for primary endpoint was rated as high for most comparisons. With respect to the clinical endpoints extracted from included studies, we calculated the difference of OS, PFS, ORR and AE between IMCT and SOC..
OS
We used fixed-effect to assess efficacy of immunotherapy through HR of OS. A total of 1,149 patients treated with immunotherapy, compared to 1,287 patients treated with standard of care shows that immunotherapy could decrease the risk of death over standard of care by 18% (HR = 0.82; 95% CI 0.74-0.90; p < 0.0001). Moderate heterogeneity was found (chi 2 =32.7, p = 0.018; I 2 =45.0%) ( Figure 3A ).
PFS
With respect to PFS, we used random-effect to assess efficacy of immunotherapy through HR of it. We pooled 8 trials. A total of 555 patients treated with IMCT, compared to 514 patients treated with SOC shows that immunotherapy could decrease the risk of recurrence over SOC by 34% (HR = 0.68, 95% CI 0.53-0.88; p = 0.008). Significant heterogeneity was found (Chi 2 = 15.75 p = 0.018; I 2 =71.0%) ( Figure 3B ).
ORR
We used random-effect to assess efficacy of IMCT by ORR. 6 trials reported ORR. It shows that tumor lesion in the IMCT group was significant compared to SOC (RR=2.56; 95% CI 2.13-2.92; p < 0.0001). Significant heterogeneity was found (Chi 2 =13.14, p=0.011; Figure 3C ).
AE
As for safety of immunotherapy regimen, some adverse events (AE) including neutropenia (59.2%), arterial hypertension (45.6%), and hematologic toxic effects (103.4%) have a relatively high incidence. In addition to them, other adverse events also existed. We used fixed-effect to assess safety of immunotherapy through RR of occurrence rate of AE. It shows significant difference between immunotherapy arm and SOC arm (RR = 1.53; 95% CI 1.24-1.90; p < 0.0001) and moderate heterogeneity (Chi 2 =43.64, p=0.012; I 2 =42.7%) ( Figure 3D ). It reveals that immunotherapy existed a certain potential safety problem.
Secondary endpoints
Subgroup meta-analyses
We try to find out factors influencing efficacy of IMCT by using subgroup meta analyses.
For different treatments of immunotherapy, all of them shows certain efficacy. Thereof DCV shows a good efficacy (HR = 0.50, 95% CI 0.28-0.88; p = 0.082). Gene therapy including Cpg/HSV-tk/PVSRIPO/AdvHSV-tk has a moderate effectiveness. However, AdvHSVtk shows a best efficacy (HR = 0.40, 95% CI 0.23-0.70; p = 0.002).
According to different disease classification, it results in immunotherapy was better for AA (HR = 0.68, 95% CI 0.39-1.19; p = 0.362) and recurrent GBM (HR = 0.83, 95% CI 0.62-1.10; p = 0.594). It also shows that there was a significant difference between GBM (HR = 0.89, 95% CI 0.79-1.00) and recurrent GBM patients (HR = 0.83, 95% CI 0.62-1.10; p = 0.020). The efficacy between RCTs and HMCTs shows no significant difference (p = 0.913).
The efficacy of open-label trials (HR = 0.79, 95% CI 0.70-0.91) is better than double-blind trials (HR = 0.85, 95% CI 0.74-0.98; p = 0.504). Nevertheless, for different recruiting area, participants in China show the biggest survival advantage through the treatment of immunotherapy ( Table 1) .
Meta-regression
Based on subgroup analyses, we found that disease classification, therapy scheme and recruiting area may be the possible heterogeneity sources.
As for OS with moderate heterogeneity, we explored its source by meta-regression. We performed meta-regression according to follow-up time, study design, disease classification, recruiting area, and therapy scheme. And it showed participants recruiting area have a big relationship with the efficacy of immunotherapy. Where it led us shows 62.32% heterogeneity between studies can be explained by above factors. (Supplementary   Table 4 )
Cumulative meta-analysis and galbraith radial plot
We did a cumulative meta analysis sorted by publication year. Despite the estimate HR was at about 1 from the year of 2000, it shows that the efficacy of immunotherapy tends to be stable at 0.82 in recent three years. (Supplementary Figure 4A) . We drew Galbraith radial plot and found no study fell outside the 95% confidence interval line, and the difference in scatter slope was minute, indicating that there was a small heterogeneity between studies. ( Figure 4B )
Sensitivity analysis
Sensitivity analysis was done to assess which study contributes to influence our current results. We found Weller 2017 [23] and Rainov 2000[25] maybe to have a potential impact on results, but the results did not materially change by deleting any study at a time ( Figure 4C ).
Publication bias
Publication bias was explored with an inverted funnel plot, which showed slight asymmetry around 95% CI and Begg's test showed a significance of bias (p=0.046) ( Figure 4D ). We use trim and fill method to identify the publication bias. However, it shows no trimming performed and data unchanged.
Discussion
We did a systematic review of the efficacy and safety of IMCT and SOC in adult HGG patients. The present results have shown that IMCT yielded better results compared to SOC and may have potential risk to increase adverse events.
The golden standard in clinical is OS. We utilize this to compare the efficacy of IMCT and SOC. Based on subgroup analysis of OS, we found immunotherapy regimens of IMCT may affect the result. The treatment of oncolytic virus with the suicide gene showed better efficacy. At the same time, the subgroup DCV existed a big difference between studies.
Vaccine treatment of mRNA-transferred into DC showed better results thereof. In addition, the route and site of administration for immunotherapy regimen also affect results. In Renata Ursu et al.'s study, they claimed that their negative result was unexpected and it may be explained by a selection bias of patients enrolled in recurrent GBM and the different mode of administration of CpG-28 [15] . Moreover, researchers have been made efforts to accelerate precision medicine. Yao 2018 et al found IDH W T TERT MT has better efficacy in GBM IMCT group [16] . Annick 2018 et al confirmed that the mutation of IDH R132 in GBM IMCT group has survival advantage [17] .
As for PFS, it is an endpoint increasingly recognized by researchers recently. When there is no significant improvement in OS, as an alternative outcome, PFS could help to explain the underlying efficacy. Nonetheless, trials reported PFS in our study are lacking. Limited studies indicated that IMCT, compared to SOC, could decrease the risk of recurrence over SOC (HR = 0.68, 95% CI 0.53-0.88; p = 0.008).
ORR is another powerful evidence of effectiveness. It was defined as follows: the proportion of patients who achieved more than 50% tumor lesion. Our study shows that tumor lesion in the IMCT group was significant compared to SOC (RR=2.56; 95% CI 2.13-2.92; p < 0.0001)
Our study aims to verify a certain efficacy of immunotherapy based on different endpoints. However, in our study, whether adopting the double-blind methods in included trials also has a certain effect to result. Thus, we appeal to more double-blind trials' advent.
For significant publication bias examined by Begg's test, the possibility of positive publication cannot be ruled out. For the number of incorporated studies is insufficient, we should have serious reservations about the evaluation of the efficacy and safety. We hope it comes to an agreement about them in the future. What's more, the safety of IMCT is a problem open to question. We found there is some potential harm to the human body (RR =1.53; 95% CI 1.23-1.90; p < 0.0001).
Because of the certain heterogeneity sources are not explored. Through subgroup analyses, we found recruiting area existed significant heterogeneity. And China benefit mostly. No comprehensive studies have explored the causes. We guess that racial difference and regional lifestyle maybe important causes.
We also conceived of checkpoint inhibitors should have earned a place as one of the immunotherapy regimens. Nevertheless, in our study, there is a vacancy for it. We excluded one publication reporting nivolumab with or without ipilimumab in patients with recurrent glioblastoma which is a phase I cohort study [18] . However, it is no doubt that checkpoint inhibitors are the most promising part of immunotherapy. Besides, a metaanalysis about it also suggests that immunotherapy has a tail-dragging effect so that use it early could have better results [19] . In the future, we hope more high-quality trials about it could emerge out of, and then we will update our reviews aiming at it. After deleting one study at a time and leaving the others the same, to observe which ones have a significant potential impact on the results. D, Begg's funnel plot with pseudo 95% confidence limits and its test illustration
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